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Seizures in children are a frightening experience for families and care providers. Because the duration of seizure activity impacts on morbidity and mortality, effective methods for 
its control should be instituted as soon as possible, preferably 
before arrival at hospital. Approximately, 4-10% of the children 
experience at least one seizure in the first 16 years of life. The 
cumulative lifetime incidence of epilepsy is 3%, and more than 
half of the cases start in childhood. The annual prevalence is 
0.5-1% [1]. Febrile seizures are the most common type of seizures 
in childhood, with an incidence of 3-4% [1].
The rapidity by which medication can be delivered to the 
systemic circulation and then to the brain plays a significant role 
in reducing the time needed to control seizures and to reduce 
opportunity for damage to the central nervous system. Speed and 
ease of delivery, particularly outside the hospital, is enhanced 
when transmucosal routes of delivery are used in place of an 
intravenous (IV) injection [2].
The emergency medicine is striving to improve the seizure 
management by improving the drug delivery techniques to 
reduce the time of seizure control. Rectal diazepam emerged first 
in this context. However, it is not as effective as IV diazepam 
in seizure control. Rectally administered diazepam results in 
variable plasma concentrations and fails to terminate 30% of the 
seizures. The tendency for diazepam to accumulate in adipose 
tissue when given in repeated doses can cause respiratory 
depression. Other disadvantage is the lower social acceptability 
of the rectal route.
Buccal and intranasal (IN) midazolam are preferable 
alternatives in the community setting. However, buccal 
administration has been found to provoke gagging, coughing, 
aspiration, and delivery is difficult when the teeth are clenched 
during a tonic–clonic seizure. IN midazolam, given as a sedative 
agent, has been shown to be safe and effective in children 
undergoing various diagnostic studies and minor surgical 
procedures [3]. IN midazolam also suppresses the seizure activity 
and improves the background electroencephalogram (EEG) in 
children with epilepsy [4,5].
MATERIALS AND METHODS
This study was conducted at the Department of Pediatrics in a 
tertiary care teaching hospital in South India. This prospective, 
randomized controlled interventional study was conducted 
after getting approval from the Institutional Ethics Committee. 
Objectives of the study were (1) to study IN versus IV midazolam 
to control generalized tonic–clonic seizures (GTCS) in children 
between 2 months and 12 years, (2) to compare the incidence of 
seizure recurrence after IN and IV midazolam, and (3) to compare 
the efficacy of both routes in control of recurrent seizures. 
Neonates, children having partial seizures, children who got 
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prior medication for the present seizure and seizures that settled 
spontaneously were excluded from the study. The sample size 
was calculated as 100, 50 in each group by applying n Master 1.0, 
using the data from a previous study [6].
Before starting the treatment, informed written consent was 
obtained from parents. In case of refusal, a complete care was 
provided following the routine protocols of the hospital. A total 
of 100 children were recruited for the study. All the patients 
were stabilized initially for airway, breathing, and circulation. 
Enrolled even number children were given IV midazolam, 
and odd number children were given commercially available 
preparation of IN midazolam as atomizer (0.5 mg/puff) as per 
recommended methods [4]. Dose was 0.2 mg/kg body weight, 
in both the routes [1,4]. Drugs were administered, and responses 
were monitored by the resident.
Time of the onset of seizure was noted in history. Time of 
seizure control after each drug was precisely calculated using 
electronic stopwatch, deducting drug administration time. 
Patients were monitored for the cessation of seizures, heart rate, 
respiratory rate, SpO2, and adverse effects of drugs. Treatment 
was considered successful if the seizures ceased within 10 min. 
Seizure that did not stop after this time was defined as treatment 
failure and other treatment was given as per the protocol of 
international league against epilepsy.
The time from the onset to seizure control and from drug 
administration to seizure control, as well as, treatment failures 
were taken for analysis. Seizures that were controlled by the drugs 
but recurred within 60 min were defined as recurrent seizures [7]. 
Recurrence was treated in the same initial line, but any further 
recurrence was treated with other medications and was taken as 
treatment failure of the recurrence. After initial control of seizures, 
all patients were investigated and further managed according to 
the diagnosis. The data recorded was tabulated and statistically 
analyzed by SPSS17 for the independent t-test and MINITAB16 
for the proportion tests.
RESULTS
Children who received IN midazolam were included in Group 1 
and who received IV midazolam in Group 2 with 50 participants 
in each group. Both groups were statistically identical in gender, 
etiology, long-term seizure medications, and age distribution. 
Etiology of seizures was seizure disorders (53%), febrile seizures 
(36%), ketotic hypoglycemia (3%), and others (8%) which 
included 2 cases of meningitis, 2 cases of brain tumor, one 
case of acute disseminated encephalomyelitis, and one case of 
diarrhea with hypocalcemia. Table 1 compares the two groups in 
2 parameters, time from seizure onset to seizure control and time 
of drug administration to seizure control. The duration of seizures 
(from onset to seizure control) ranged from 2 to 35 min in IN group 
and 2 min to 30 min in IV group with a mean of 8.54 and 7.98, 
respectively (p=0.330). Table 2 compares the two groups in three 
parameters such as treatment failure, recurrences, and treatment 
failure of recurrences. On comparing the treatment failures in both 
groups, no significant difference was found (p=0.0137) suggesting 
that both routes were equally effective. Recurrences and treatment 
failure of recurrences were also similar in both groups.
DISCUSSION
We conducted this study as most of the previous studies compared 
IN midazolam with IV or rectal diazepam, and there were only 
very few studies comparing IN and IV midazolam in childhood 
seizures. Our study suggests that IN midazolam is an effective 
and easy alternative to IV midazolam. In our study, there was no 
significant difference in the duration of seizures (from onset to 
seizure control) between the two groups. IN midazolam was as 
effective as IV midazolam in the control of GTCS based on the 
time of onset to seizure control. Study by Lahat et al. in children 
with febrile seizures had yielded similar results [8]. The interval 
from drug administration to seizure control was better in IV group 
than the IN group (p<0.05). However, Sharma and Harish found 
that intranasal midazolam was superior in seizure control from 
the time of drug administration [6].
In our study, both the routes were equally effective as no 
difference was found in treatment failures. Similarly, recurrences 
and treatment failure of recurrences were also similar in both 
groups. Therefore, the two routes of administration of midazolam 
were comparable in time taken to control seizures, treatment 
failure, recurrences, and treatment failure of recurrences. Several 
other studies also support these results [9-11].
Table 1: Group statistics
Variable Study group Numbers Mean±standard 
deviation (minutes)
Time of seizure 
control from 
onset
Group 1 (IN) 50 8.5400±6.86966
Group 2 (IV) 50 7.9800±5.75872
p=0.330
Time of 
seizure control 
from drug 
administration*
Group 1 (IN) 50 3.7684±1.4722
Group 2 (IV) 50 2.9428±0.9811
p<0.05
*Excluding administration time. IN: Intranasal, IV: Intravenous
Table 2: Group statistics
Variable Group* Number Total 
number 
children
Proportion 
of failure
Treatment failure Group 1 4 50 0.08
Group 2 9 50 0.18
p=0.1371
Recurrence of 
seizure
Group 1 6 50 0.12
Group 2 9 50 0.18
p=0.401
Treatment failure 
of recurrence
Group 1 2 50 0.04
Group 2 2 50 0.04
p=1.0
*Group 1 - IN and Group 2 - IV midazolam. IN: Intranasal, IV: Intravenous
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Intranasal sprays of medication, intended for systemic drug 
absorption, are generally designed to target the turbinates on the 
lateral wall of nasal cavity. This region of nasal cavity is covered 
by a thin monolayer ciliated epithelium with abundant blood 
supply and large surface area of 180 cm2. These conditions are 
ideal to permit passive transcellular and paracellular diffusion 
of medications [2]. This bypasses the gut metabolism, so 
adequate blood levels are achieved faster. Use of IN midazolam 
has been reported since 1988 [12]. Midazolam, a water-soluble 
benzodiazepine, becomes fat soluble at physiological pH, allowing 
it to cross the nasal mucosa into adjacent tissues including CSF, 
resulting in rapid onset of action. Intranasal route obviates the 
need for IV access, rapid in effect, and avoids the pain of IM 
administration. The safety margin of midazolam and easiness of 
administration allows prehospital use of this medication even by 
parents [13,14] so that the seizure control and outcome will be 
good.
Limitations of this study were that we conducted the study in 
GTCS only and excluded focal seizures with the assumption that 
the most focal seizures are symptomatic and difficult to control. 
Second, we have not assessed the EEG control of seizures. 
Therefore, more studies are required to compare these two routes 
of administration of midazolam.
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